Obsidian Therapeutics Appoints Jan ter Meulen, M.D., Ph.D., as Chief Scientific Officer

Obsidian Therapeutics, Inc., a biotechnology company pioneering controllable cell and gene therapies, today announced that Jan Henrik ter Meulen, M.D., Ph.D. , has been appointed Chief Scientific Officer. Dr. ter Meulen will lead Obsidian's ongoing efforts in the application of the Company's proprietary cytoDRiVE ™ platfor